Application of cell surface engineered yeast for the development of drugs against influenza virus infection

Influenza and RNA Viruses: Emergence, Classification and Management

Volumn , Issue , 2014, Pages 91-110

  Yamada, Junki ^a   Miura, Natsuko ^a,b   Shigemori, Tomohiro ^a   Kuroda, Kouichi ^a   Ueda, Mitsuyoshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84954309490     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (48)

1. Palese, P., Young, J. F. (1982). Variation of influenza A, B, and C viruses. Science, 215, 1468-1474.
2. Fouchier, R. A., Munster, V., Wallensten, A., Bestebroer, T. M., Herfst, S., Smith, D., et al. (2005). Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. Journal of Virology, 79, 2814-2822.
3. Baker, A. T., Varghese, J. N., Laver, W. G., Air, G. M., Colman, P. M. (1987). Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins, 2, 111-117.
4. Shinde, V., Bridges, C. B., Uyeki, T. M., Shu, B., Balish, A., Xu, X., et al. (2009). Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. The New England Journal of Medicine, 360, 2616-2625.
5. Nayak, D. P., Balogun, R. A., Yamada, H., Zhou, Z. H., Barman, S. (2009). Influenza virus morphogenesis and budding. Virus Research, 143, 147.
6. Both, G. W., Sleigh, M. J., Cox, N. J., Kendal, A. P. (1983). Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. Journal of Virology, 48, 52-60.
7. Carrat, F., Flahault, A. (2007). Influenza vaccine: the challenge of antigenic drift. Vaccine, 25, 6852-6862.
8. Cox, N. J., Subbarao, K. (2000). Global epidemiology of influenza: past and present. Annual Review of Medicine, 51, 407-421.
9. Holmes, E. C., Ghedin, E., Miller, N., Taylor, J., Bao, Y., St George, K., et al. (2005). Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. PLoS Biology, 3, e300.
10. Neumann, G., Noda, T., Kawaoka, Y. (2009). Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature, 459, 931-939.
11. Claas, E. C., Osterhaus, A. D., van Beek, R., De Jong, J. C., Rimmelzwaan, G. F., Senne, D. A., et al. (1998). Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. The Lancet, 351, 472-477.
12. Wilson, I., Skehel, J., Wiley, D. (1981). Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 andangst; resolution. Nature, 289, 366-373.
13. Steel, J., Lowen, A. C., Wang, T. T., Yondola, M., Gao, Q., Haye, K., et al. (2010). Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio, 1, e00018.
14. Gething, M. J., Doms, R. W., York, D., White, J. (1986). Studies on the mechanism of membrane fusion: site-specific mutagenesis of the hemagglutinin of influenza virus. The Journal of Cell Biology, 102, 11-23.
15. Wiley, D. C., Skehel, J. J. (1987). The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annual Review of Biochemistry, 56, 365-394.
16. Sauter, N. K., Bednarski, M. D., Wurzburg, B. A., Hanson, J. E., Whitesides, G. M., Skehel, J. J., et al. (1989). Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. Biochemistry, 28, 8388-8396.
17. Durrer, P., Galli, C., Hoenke, S., Corti, C., Glück, R., Vorherr, T., et al. (1996). H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region. Journal of Biological Chemistry, 271, 13417-13421.
18. Cross, K. J., Langley, W. A., Russell, R. J., Skehel, J. J., Steinhauer, D. A. (2009). Composition and functions of the influenza fusion peptide. Protein and Peptide Letters, 16, 766-778.
19. Skehel, J. J., Wiley, D. C. (2000). Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annual Review of Biochemistry, 69, 531-569.
20. Moscona, A. (2005). Neuraminidase inhibitors for influenza. The New England Journal of Medicine, 353, 1363-1373.
21. Xu, R., Zhu, X., McBride, R., Nycholat, C. M., Yu, W., Paulson, J. C., et al. (2012). Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic. Journal of Virology, 86, 9221-9232.
22. Hay, A. J., Wolstenholme, A. J., Skehel, J. J., Smith, M. H. (1985). The molecular basis of the specific anti-influenza action of amantadine. The EMBO Journal, 4, 3021-3024.
23. Pinto, L. H., Holsinger, L. J., Lamb, R. A. (1992). Influenza virus M2 protein has ion channel activity. Cell, 69, 517-528.
24. Stoof, J. C., Booij, J., Drukarch, B., Wolters, E. C. (1992). The anti parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. European Journal of Pharmacology, 213, 439-443.
25. Hayden, F. G., Belshe, R. B., Clover, R. D., Hay, A. J., Oakes, M. G., Soo, W. (1989). Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. The New England Journal of Medicine, 321, 1696-1702.
26. Russell, R. J., Kerry, P. S., Stevens, D. J., Steinhauer, D. A., Martin, S. R., Gamblin, S. J., et al. (2008). Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proceedings of the National Academy of Sciences US, 105, 17736-17741.
27. Garten, W., Stieneke, A., Shaw, E., Wikstrom, P., Klenk, H. D. (1989). Inhibition of proteolytic activation of influenza virus hemagglutinin by specific peptidyl chloroalkyl ketones. Virology, 172, 25-31.
28. Matsubara, T., Onishi, A., Saito, T., Shimada, A., Inoue, H., Taki, T., et al. (2010). Sialic acid-mimic peptides as hemagglutinin inhibitors for antiinfluenza therapy. Journal of Medicinal Chemistry, 53, 4441-4449.
29. Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H., Jongeneelen, M., Throsby, M., et al. (2009). Antibody recognition of a highly conserved influenza virus epitope. Science, 324, 246-251.
30. Von Itzstein, M., Wu, W. Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., et al. (1993). Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 363, 418-423.
31. Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., et al. (1997). Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent antiinfluenza activity. Journal of the American Chemical Society, 119, 681-690.
32. Ives, J. A., Carr, J. A., Mendel, D. B., Tai, C. Y., Lambkin, R., Kelly, L., et al. (2002). The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Research, 55, 307-317.
33. Staschke, K. A., Colacino, J. M., Baxter, A. J., Air, G. M., Bansal, A., Hornback, W. J., et al. (1995). Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology, 214, 642-646.
34. Babu, Y. S., Chand, P., Bantia, S., Kotian, P., Dehghani, A., El-Kattan, Y., et al. (2000). BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. Journal of Medicinal Chemistry, 43, 3482-3486.
35. Yamamoto, T., Kumazawa, H., Inami, K., Teshima, T., Shiba, T. (1992). Syntheses of sialic-acid isomers with inhibitory activity against neuraminidase. Tetrahedron Letters, 33, 5791-5794.
36. Gubareva, L. V., Kaiser, L., Hayden, F. G. (2000). Influenza virus neuraminidase inhibitors. The Lancet, 355, 827-835.
37. Bantia, S., Arnold, C. S., Parker, C. D., Upshaw, R., Chand, P. (2006). Antiinfluenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Research, 69, 39-45.
38. Ueda, M. (2011). Revolutionary protein engineering using molecular display. Protein Engineering: Design, Selection and Applications (Nova Science Publisher), 73-80.
39. Fushimi, T., Miura, N., Shintani, H., Tsunoda, H., Kuroda, K., Ueda, M. (2013). Mutant firefly luciferases with improved specific activity and dATP discrimination constructed by yeast cell surface engineering. Applied Microbiology and Biotechnology, 97, 4003-4011.
40. Shigemori, T., Nagayama, M., Yamada, J., Miura, N., Yongkiettrakul, S., Kuroda, K., et al. (2013). Construction of a convenient system for easily screening inhibitors of mutated influenza virus neuraminidases. FEBS Open Bio, 3, 484-489.
41. Kortemme, T., Joachimiak, L. A., Bullock, A. N., Schuler, A. D., Stoddard, B. L., Baker, D. (2004). Computational redesign of protein-protein interaction specificity. Nature Structural and Molecular Biology, 11, 371- 379.
42. Fleishman, S. J., Whitehead, T. A., Ekiert, D. C., Dreyfus, C., Corn, J. E., Strauch, E. M., et al. (2011). Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science, 332, 816-821.
43. Whitehead, T. A., Chevalier, A., Song, Y., Dreyfus, C., Fleishman, S. J., De Mattos, C., et al. (2012). Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nature Biotechnology, 30, 543-548.
44. Han, T., Sui, J., Bennett, A. S., Liddington, R. C., Donis, R. O., Zhu, Q., et al. (2011). Fine epitope mapping of monoclonal antibodies against hemagglutinin of a highly pathogenic H5N1 influenza virus using yeast surface display. Biochemical and Biophysical Research Communications, 409, 253-259.
45. Tamaru, Y., Ohtsuka, M., Kato, K., Manabe, S., Kuroda, K., Sanada, M., et al. (2006). Application of the arming system for the expression of the 380R antigen from red sea bream iridovirus (RSIV) on the surface of yeast cells: a first step for the development of an oral vaccine. Biotechnology Progress, 22, 949-953.
46. Shibasaki, S., Ueda, M. (2010). Development of yeast molecular display systems focused on therapeutic proteins, enzymes, and foods: functional analysis of proteins and its application to bioconversion. Recent Patent Biotechnology, 4, 198-213.
47. Shibasaki, S., Aoki, W., Nomura, T., Miyoshi, A., Tafuku, S., Sewaki, T., et al. (2013). An oral vaccine against candidiasis generated by a yeast molecular display system. Pathogens and Disease, 69, 262-268.
48. Wasilenko, J. L., Sarmento, L., Spatz, S., Pantin-Jackwood, M. (2010). Cell surface display of highly pathogenic avian influenza virus hemagglutinin on the surface of Pichia pastoris cells using alpha-agglutinin for production of oral vaccines. Biotechnology Progress, 26, 542-547.